An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report

Transfusion and Apheresis Science

Volumn 52, Issue 3, 2015, Pages 314-316

  Sengul Samanci, Nilay ^a   Ayer, Mesut ^a   Ergen, Abdulkadir ^a   Ozturk, Savas ^a  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Atypical hemolytic uremic syndrome; Eculizumab; Plazma exchange

Indexed keywords

AMLODIPINE; CREATININE; DOXAZOSIN; ECULIZUMAB; FRESH FROZEN PLASMA; FUROSEMIDE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE; METHYLDOPA; METOPROLOL; PNEUMOCOCCUS VACCINE; MONOCLONAL ANTIBODY;

ADULT; ANTIHYPERTENSIVE THERAPY; ANURIA; ARTICLE; BLOOD SMEAR; CASE REPORT; CREATININE BLOOD LEVEL; DOPPLER ECHOGRAPHY; DYSPNEA; ERYTHROCYTE URINE LEVEL; FECES CULTURE; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPERTENSION; INFLUENZA B; INFLUENZA VACCINATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MALE; MENINGOCOCCOSIS; MIDDLE AGED; PHYSICAL EXAMINATION; PLASMAPHERESIS; PNEUMOCOCCAL INFECTION; PROTEIN BLOOD LEVEL; TREATMENT DURATION; URINALYSIS; VACCINATION; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; DISEASE COURSE; IMMUNOLOGY; KIDNEY; PATHOLOGY; PROCEDURES; RENAL REPLACEMENT THERAPY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; DISEASE PROGRESSION; HUMANS; KIDNEY; MALE; MIDDLE AGED; PLASMA EXCHANGE; RENAL DIALYSIS; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME;

EID: 84930541447     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2015.01.006     Document Type: Article

References (9)

1. Loirat C., Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011, 6:60.
2. Lee B.H., Kwak S.H., Shin J.I., et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. Pediatr Res 2009, 66(3):336-340.
3. Bresin E., Daina E., Noris M., et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006, 1(1):88-99.
4. Noris M., Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16(4):1035-1050.
5. Nester C.M., Thomas C.P. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?. Hematology Am Soc Hematol Educ Program 2012, 2012:617-625.
6. Noris M., Caprioli J., Bresin E., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010, 5(10):1844-1859.
7. Kavanagh D., Goodship T.H., Richards A. Atypical haemolytic uraemic syndrome. Br Med Bull 2006, 77-78:5-22.
8. Gruppo R.A., Rother R.P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009, 360(5):544-546.
9. Zuber J., Le Quintrec M., Sberro-Soussan R., et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011, 7(1):23-35.